MedPath

Aldesleukin

Generic Name
Aldesleukin
Brand Names
Proleukin
Drug Type
Biotech
CAS Number
110942-02-4
Unique Ingredient Identifier
M89N0Q7EQR
Background

Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.

Indication

For treatment of adults with metastatic renal cell carcinoma.

Associated Conditions
Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
Clinical Trials
Related News

Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic in Melanoma Treatment

• Aulos Bioscience will present new Phase 2 data for AU-007, an AI-designed monoclonal antibody targeting IL-2, showing promising results in second-line melanoma treatment at the upcoming AACR Annual Meeting. • AU-007's unique mechanism prevents IL-2 from binding to regulatory T cells while allowing it to activate effector T cells and NK cells, potentially overcoming limitations of traditional IL-2 therapies. • The novel therapeutic may significantly reduce serious side effects associated with high-dose IL-2 therapy, including vascular leak syndrome and pulmonary edema, by preventing IL-2 binding to CD25-containing receptors.

Iovance Biotherapeutics Continues Expansion with Nearly 300 New Stock Option Grants to Support TIL Therapy Development

• Iovance Biotherapeutics granted inducement stock options covering 297,600 shares to fifty new employees on April 17, 2025, following similar grants of 308,710 shares to forty-three employees in March. • The company is expanding its workforce to support the commercialization of Amtagvi, the first FDA-approved T-cell therapy for a solid tumor indication, and further development of its tumor infiltrating lymphocyte (TIL) platform. • Each stock option has a three-year vesting period with an exercise price of $3.06 per share, reflecting Iovance's strategic investment in human capital to advance its cancer immunotherapy pipeline.

FDA Approves ORLYNVAH™: First New Oral Treatment for Uncomplicated UTIs in 25 Years

• Iterum Therapeutics receives FDA approval for ORLYNVAH™, marking the first branded uncomplicated UTI treatment to enter the U.S. market in over 25 years and the first oral penem antibiotic approved in the country. • The drug demonstrates significant potential against multi-drug resistant pathogens, specifically targeting Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis in adult women with limited treatment options. • Iterum reports $24.1 million in cash reserves as of December 2024, with funding projected to sustain operations into the second half of 2025 while pursuing pre-commercialization activities.

Iovance Biotherapeutics Reports Strong Amtagvi Sales and Outlines Expansion Strategy

• Iovance Biotherapeutics reported $58.6 million in total product revenue for Q3 2024, driven by robust demand for Amtagvi and Proleukin, reaffirming revenue guidance of $160-$165M for FY24. • Amtagvi, a novel TIL therapy, has seen significant adoption with 146 patients infused since April 2024, and is on track to expand into new markets with regulatory submissions underway in the UK, EU, and Canada. • Enrollment is accelerating in the IOV-LUN-202 Phase 2 trial for post-anti-PD-1 NSCLC, with potential for accelerated U.S. approval in 2027, alongside advancements in frontline melanoma and endometrial cancer treatments. • Iovance is expanding its manufacturing capacity to treat over 5,000 patients annually and holds patents expected to provide Amtagvi with exclusivity through at least 2042, ensuring long-term market leadership.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy